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Abstract: Plant hormones are small regulatory molecules that exert pharmacological actions in
mammalian cells such as anti-oxidative and pro-metabolic effects. Kinetin belongs to the group of
plant hormones cytokinin and has been associated with modulatory functions in mammalian cells.
The mammalian adenosine receptor (A2a-R) is known to modulate multiple physiological responses
in animal cells. Here, we describe that kinetin binds to the adenosine receptor (A2a-R) through the
Asn253 residue in an adenosine dependent manner. To harness the beneficial effects of kinetin for
future human use, we assess its acute toxicity by analyzing different biochemical and histological
markers in rats. Kinetin at a dose below 1 mg/kg had no adverse effects on the serum level of glucose
or on the activity of serum alanine transaminase (ALT) or aspartate aminotransferase (AST) enzymes
in the kinetin treated rats. Whereas, creatinine levels increased after a kinetin treatment at a dose
of 0.5 mg/kg. Furthermore, 5 mg/kg treated kinetin rats showed normal renal corpuscles, but a
mild degeneration was observed in the renal glomeruli and renal tubules, as well as few degenerated
hepatocytes were also observed in the liver. Kinetin doses below 5 mg/kg did not show any localized
toxicity in the liver and kidney tissues. In addition to unraveling the binding interaction between
kinetin and A2a-R, our findings suggest safe dose limits for the future use of kinetin as a therapeutic
and modulatory agent against various pathophysiological conditions.
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Screening existing or recently discovered agents for alternative activities and a new
therapeutic application has become an attractive approach [1–6]. Natural products-derived
compounds exhibit various pharmacological effects and modulate, in vitro and in vivo,
different signaling pathways involved in proliferation, migration, angiogenesis, apoptosis,
oxidative stress, and inflammation-related disorders. Recently, many researchers began
to investigate new biological activities for known or uncharacterized natural compounds.
This is a new repurposing strategy to identify new therapeutic or prophylactic agents
benefitting from the safety and apparent activities of these natural compounds [7–12]. One
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of the highlighted natural compounds which showed promising pharmacological activities
in human cells are plant hormones such as cytokinins [13–15].
The small regulatory molecule N6-furfuryladenine (N6FFA) is commonly known as
kinetin. It is a type of plant growth regulator, and belongs to the group of cytokinins
(CKs) [16]. In plants, CK signaling operates through a two-components system (TCS),
where the binding of CKs to the CHASE-domain of sensor histidine kinases (HKs) initiates
a phosphorylation cascade involving histidine phosphotransfer proteins (HPTs) and B-type
response regulators (B-ARRs) [17,18]. The B-type ARRs activate the expression of A-type
response regulators (A-ARRS), which inhibit the signal of CKs in plants [17]. Similar to
various other CK types, kinetin also binds to almost all known CKs receptors and causes
analogous physiological responses in plants [17]. Understanding the signaling pathways
of CKs in mammalian cells is still a terra incognita, as mammalian cells are devoid of the
analogous TCS known from plants [19]. Despite this fundamental discrepancy, CKs get a
lot of attention for their anti-ageing [20], neuro-protective [21,22], anti-cancerous [23], and
anti-inflammatory [24] effects evident after tests in various types of mammalian cell lines.
In plants, kinetin binds to the CHASE-domain of Arabidopsis histidine kinase 4 (AHK4)
and initiates a cascade of phosphorylation events to induce the expression of cytokinin
response genes. In addition to many interesting functions that kinetin performs in mammalian cellular systems, the binding target sites of this important small molecule are not
well elucidated until now. Only a few of the kinetin binding proteins (KPBs) have been
studied so far. One of the putative KBPs is the adenosine receptor A2a-R, which is a drug
target site for many cellular processes such as neuroprotection, cell proliferation, vascular
regulation, as well as immunomodulatory functions [6,7,9]. Until now, only four types
of adenosine receptors (A1R, A2aR, A2bR, and A3R) have been characterized. Among
them, A1R and A3R belong to the group of G-coupled proteins that inhibit the adenylate
cyclase-mediated production of the cAMP. In contrast, A2aR and A2bR belong to Go/Gscoupled receptors that raise intracellular levels of cAMP and cause an anti-inflammatory
response. Similar to adenosine and its analogs, which exert diverse anti-inflammatory
effects such as the inhibition of TCR-mediated activation and cytokine production by T cells.
One of the possible suggested mechanisms, which in this study was examined in silico
and could explain the kinetin mediated effects in the mammalian cells is the binding of
kinetin to A2a-R. The clear binding interactions observed in silico, together with the found
pharmacological and protective effects suggest that the analogues modulatory functions
in mammalian cellular systems are known from plants. One prominent previous study
supporting our notion is the inhibition of the T lymphocyte activity via A2a-R activation
by the plant hormone zeatin riboside [24]. Moreover, only the riboside form of kinetin has
been shown to interact with A2a-R in invoking neuroprotection in a Huntington’s disease
(HD) model [21]. However, a recent study demonstrated that kinetin in its native form
can also protect HD-models [22]. Assessing the binding dynamics of kinetin for A2a-R
with structural biology approaches helps better elucidate important residues for functional
studies about kinetin as a potential modulator of diverse responses through the A2a-R
receptor in mammalian cells.
As a first step before elucidating and applying the outcomes from the in silico modeling, it was important to examine the safety of using kinetin in an in vivo system and
evaluate the safe, non-toxic doses which then can be scrutinized further for biological
activity and therapeutic actions in future studies.
The in vitro effects of kinetin in terms of protection against oxidative stress have
been extensively analyzed for the first time in a report by our group in various cellular
systems with diverse potencies such as a human promyelocytic cell line (HL-60), a human
keratinocyte cell line (HaCaT), an epithelial rat kidney cell line (NRK), and even in freshly
isolated human lymphocytes [25,26]. It was demonstrated that kinetin concentrations
below 100 nM can protect mammalian cells against genotoxicity induced cell death, as
well as apoptosis [25]. In contrast, kinetin concentrations above 100 nM induce moderate
genotoxicity, as well as cytotoxicity in the treated cells [10]. Likewise, the exogenous
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application of 1–10 µM concentrations of kinetin has shown no significant toxicity effects
on the nerve cells [22]. More recently, it has been demonstrated that human promyelocytic
HL-60 cells treated with less than 500 nM kinetin did not show a significant reduction
in cell viability and genotoxicity [26]. However, higher kinetin concentrations beyond
500 nM induced both cytotoxicity and genotoxicity in the treated cells. Moreover, the
H2 O2 treated cells were protected from oxidative burst when simultaneously treated with
a low concentration of kinetin (100 nM). However, higher kinetin concentrations (more
than 500 nM) failed to rescue cells from the oxidative burst [25,26]. It is noteworthy to
mention that all these previous studies pertinent to the rescuing effects of kinetin have been
conducted on diverse cell lines. Despite these in vitro studies about the protective effects
of kinetin against cellular toxicity, literature is scarce about the in vivo effects of kinetin.
One prominent study in this context showed that there is no toxicity in mice administered
kinetin intraperitonealy or orally at doses of 4.17 or 6.53 mg/kg [22]. Moreover, kinetin
treatments furnished a visible improvement including curing the severe neurological
conditions of Huntington’s disease [22].
To broaden the scope of kinetin as a future therapeutic agent against oxidative stress,
as well as a modulatory agent, it is directly required to assess the in vivo toxicity of kinetin
in an animal model. In the present study, we applied structural biology approaches to
study the interaction between A2a-R and kinetin to find important binding residues for
later functional studies and assays. We performed a metanalysis on the expression of the
A2a-R gene across diverse anatomical parts including kidney and liver tissues. The present
study investigated, for the first time the systemic effects of kinetin in adult male albino rats
after the acute treatment with different doses of kinetin. Our study provides a baseline
for the future use of kinetin as a potential therapeutic agent against cellular inflammatory
responses and oxidative stress arising from various pathophysiological conditions.
2. Results and Discussion
2.1. The Interaction between Kinetin and A2a-R Receptor Provides Mechanistic Insights into the
Kinetin Action
Previous studies have demonstrated the anti-ageing, anti-inflammatory, immunomodulatory, and neuro-protective effects of kinetin in mammalian cells [20–23]. Despite the lack
of understanding of its complete detailed biogenesis [22] or its targets in human cellular
proteome and functional implications for mammalian cells [26], kinetin caught much attention recently for its potential therapeutic applications. One of the putative kinetin binding
targets (KBP) is the adenosine receptor. Here, the binding of zeatin-riboside (cytokinin
type, kinetin analogue) has been shown, for example, to inhibit the T lymphocyte activity
via the adenosine A2a-R receptor activation [21]. Moreover, a riboside form of kinetin was
shown to interact with A2a-R in mediating the neuroprotection in HD models [24]. Most of
the CKs binding domains (CHASE-domain of histidine kinases) are studied in plants and
microbial cells [18,19] and their binding sites in mammalian cells have not been systematically investigated. Similar to kinetin, adenosine is an adenine with added ribose sugar
(Figure 1A) that binds to A2a-R, and so does the naturally occurring zeatin-riboside [21].
To get structural insights into the binding dynamics of kinetin to A2a-R, and as a first
step to study the detailed action of kinetin at the molecular level before any experimental
studies, we first compared and visualized the crystal structure of Arabidospsis AHK4 (plant
cytokinin receptor) in the complex with kinetin along with the crystal structure of the
human A2a-R complex with adenosine (Figure 1). We located the interacting residues of
both these complexes: AHK4 A chain residues Asp262 and Leu 284 interact with kinetin
(Figure 1B). Likewise, A2a-R residues Glu169, Asn253, Ser277, and His278 interact with
adenosine (Figure 1C). Apparently, there are no common residues between Arabidospsis
AHK4 and human A2a-R in their respective binding pockets for kinetin and adenosine.
Then, we docked kinetin to the human A2a-R using the Autogrid and Autodock software.
As a positive control, kinetin was also docked to the A chain of Arabidospsis AHK4. The
visualization of kinetin docked to the AHK4 A chain shows that Leu284 and Asp262 are
the residues through which kinetin binds to Arabidospsis AHK4 A with a minimum binding
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2.2. Systemic Effects of Kinetin in Albino Male Rats in Terms of Morbidity and Mortality
We previously studied the protective effects of kinetin against oxidative stress under
genotoxic, as well as cytotoxic conditions in a variety of cell lines [25,26]. Almost all these
studies have been conducted on cell lines through in vitro assays. Despite the experimental
convenience that in vitro studies offer, these are unable to provide systemic insights into the
toxicity, vitality, and efficacy of the administered bioactive compound to the cell culture. To
harness the therapeutic potential of kinetin, we conducted an in vivo study after injecting
various doses into adult male albino rats. Owing to their similarity with the human
digestive system and having a food composition similar to that typically eaten by humans,
male albino rats are very suitable for experimental replicates and data reproducibility due
to their small size and ease in handling in toxicological examinations.
In this study, we assessed the acute toxicity (14 days) of low and high concentrations
of kinetin in adult male albino rats. We used a range of kinetin doses such as 0, 0.25, 0.5, 1,
and 5 mg/kg. In our previous study [25,26], we observed a biphasic response of protection
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and vulnerability in cell lines after the kinetin treatment with low (below 500 nM) and high
(above 500 nM) concentrations. Taking that into account, we assessed the mortality rate
of the treated animals. We did not observe any mortality (0%) or morbidity (0%) in the
treated animals (all together 30 animals). Furthermore, we observed the treated animals for
physical changes and daily activities during the 14 days treatment period with both high
and low kinetin doses. We did not observe any visible changes in the physical activities of
the treated rats. There are no previous reports on the correlation between the toxicological
assessment of increased cytokinin concentrations in mammals. However, higher cytokinin
concentrations led to the accumulation of antimicrobial compounds in plants that can kill
plant pathogens [28]. Similarly, the increased production of cytokinin in Mycobacterium
tuberculosis increased bacterial hypersensitivity [27]. Likewise, a higher cytokinin containing plant extracts when fed to insect larvae, caused twitching and thrashing activities in
comparison to the insects fed with non-transgenic control leaves [29]. The lack of adverse
effects of kinetin in the treated rats particularly at higher doses can be attributed to the
process of detoxification that may occur at the organismal level to neutralize the toxicity
of kinetin.
2.3. Kinetin Mediated Toxicity and the Serum Level of Metabolites and Enzymes Activity
The liver and kidney are among the most vital and central detoxification organs that
are affected by the toxicity of compounds. Their damage can lead to severe complications
such as renal failure, hepatic cirrhosis, or even death. To assess the systemic effects of
kinetin, we collected serum, liver, and kidney samples of the treated rats and control groups.
Then, we assessed the level of different markers such as glucose level, alanine transaminase
(ALT), aspartate aminotransferase (AST), and creatinine in the serum of the treated rats
to determine the systemic (toxic) effects of various doses of kinetin. The lower doses of
kinetin such as 0.25 and 0.5 mg/kg body weight did not increase the level of glucose as
compared to the control groups (Figure 3A). However, higher doses such as 1 and 5 mg/kg
caused a significant increase in the serum glucose level. Likewise, we did not observe any
significant difference in the serum ALT and AST enzymes for treated rats in comparison
to the control groups (Figure 3B,C). However, similar to the serum glucose level, we also
noticed a significant increase in the activity of both these liver enzymes in the serum of the
1 and 5 mg/kg kinetin treated rats. To get insight into the impact of the kinetin treatment
on kidney functions, we determined the levels of creatinine in the serum of treated and
control groups. Unlike serum glucose and liver functional enzyme markers, we found a
significant increase in serum creatinine levels at 0.25 mg/kg kinetin dose and the difference
was even more pronounced at higher doses of the kinetin treatment (Figure 3D). Taken
together, these results signify a dose dependent response of kinetin such that lower doses
have no toxic effects on renal and hepatic functions. However, higher kinetin doses lead
to potential malfunctioning in the activities of both these vital organs. In comparison to
the liver, the kidney samples showed a sign of toxicity even at 0.25 mg/kg body weight
of the kinetin treatment. The early appearance of toxicity in the kidney tissue shows its
differential response to toxicity in comparison to the liver tissue, which better withstands
toxic effects owing to the detoxification mechanisms it applies in the routine. These results
further substantiate the validity of our previous findings [25,26] of the in vitro effects of
kinetin on treated cell lines, where higher kinetin doses showed genotoxic and cytotoxic
effects on the cells and lower doses further protected cells against the effects of genotoxic
as well as cytotoxic agents.
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3. Materials and Methods
3.1. Docking of Kinetin to the A2a-R Receptor
A local pairwise sequence alignment of AHK4 and A2A-R sequences was performed
using the EMBOSS Water online tool. From the protein data bank (PDB), crystal structures
of Arabidopsis AHK4 in complex with kinetin and in the human A2a-R receptor with
adenosine bound were obtained with accession codes 3T4S and 2YDO, respectively. For a
structural alignment of the AHK4 A chain and A2a-R we used the PyMol software. The
crystal structure of AHK4 in complex with kinetin was retrieved from the PDB database.
We used PyMol to visualize AHK4 residues interacting with kinetin. Likewise, the crystal
structure of A2a-R was obtained in complex with adenosine and visualized by using
PyMol. Eventually, kinetin was docked first to AHK4 and then to A2a-R using AutoGrid
and AutoDock softwares. The graphical user interface Autodock tools (ADT) were also
utilized. The conversions of the files were performed using the Open Babel software.
3.2. Experimental Animals
Kinetin was obtained from Sigma-Aldrich (Dorset, Germany), if not mentioned, all
other chemicals or solvents were purchased from Santa Cruz Biotechnology (Heidelberg,
Germany). This study was conducted on adult male albino rats (weight 150–180 g) and
approved by the Research Ethics Committee for Animal Experimentation, Department of
Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, Egypt (project code
no. 54/2019). Rats were housed and bred under standardized conditions in the pre-clinical
animal house. They were kept in mesh-bottomed stainless-steel cages (six per cage), fed a
standard diet, and allowed free access to drinking water. The animals were acclimatized to
the environment for 1 week before commencement of the experiments. All the conditions
were carefully maintained to minimize animal suffering.
3.3. Experimental Design
After an adaptation period of 7 days, rats were randomly divided into five groups
of six animals each. Treatments were then carried out according to the following design
Group 1: Served as the normal control group, which received the saline only for 14 days.
Group 2, 3, 4, and 5: Received different doses of kinetin (0.25, 0.5, 1.0, and 5.0 mg/kg body
weight, respectively) for 14 days through an intraperitoneal injection.
3.4. Biochemical Assays
Freshly collected blood samples after scarification were centrifuged at 3000 rpm for
10 min. The obtained clear serum was used for measuring the levels of glucose, ALT,
AST, and creatinine using commercially available colorimetric assay kits (Sigma-Aldrich),
according to the standard procedures [30].
3.5. Histopathological Examination
All the animals were sacrificed, by the end of the experiment the liver and kidney
were collected and fixed in 10% of neutral buffered formalin. The excised organs were
routinely processed dehydrated in ascending grades of ethanol and embedded in Paraffin
wax. Then, the obtained blocks were sectioned at 4 to 5 mm thickness. The obtained tissue
sections were collected on clean and dry glass slides, deparaffinized, and stained with the
Hematoxylin and Eosin stain [31]. Then, the sections were examined and observed under
a light microscope at 100, 200, and 400× magnification (Leika DMRBE, Germany) for the
determination of pathological alterations.
4. Conclusions and Outlook
In conclusion, our results from the structural biology analysis identified similar binding residues and binding modes between kinetin and A2a-R, as a first intriguing receptor
target suggested by the in silico analysis. Such interactions can mediate the observed
regulatory actions of kinetin into mammalian cells.
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Our immunohistochemistry analysis hinted on the acute toxicity of rats only for doses
of 5 mg/kg kinetin or higher, which is supported by a previous study (from a neurological
point of view) where the intraperitoneal administration of 4.17 mg/kg of kinetin better
protected the HD mouse model from severe neurological conditions without inducing toxicity in the treated mice [22]. Likewise, when administered at 5 mg/kg, kinetin significantly
inhibited the apoptosis and promoted the proliferation of splenic lymphocytes. Moreover,
kinetin did effectively enhance the immune power of aging rats and slow down the aging
process [32]. Furthermore, it was observed that the treatment with kinetin, at doses of 4 and
6 mg/kg body weight, may lower the risk of thromboembolic-related disorders and was
effective in reducing the mortality of acute pulmonary thromboembolism in mice [33]. It is
challenging to compare the body weight in vivo kinetin administration doses to the in vitro
kinetin concentrations. The latter are in nano-molar or micro-molar concentrations, as we
previously demonstrated in in vitro studies using cell lines [25,26]. However, previous
in vivo studies (although somewhat fragmentary) [32] demonstrated that under various
conditions, the 5 mg/kg body weight kinetin dose retains pharmacological effects. Thus,
our study provides a first baseline for future studies harnessing the effects of kinetin as a
potential therapeutic agent [34] in mitigating oxidative stress and potentially promoting
beneficial modulatory responses of kinetins. However, there are many open questions
regarding the fundamental molecular understanding of kinetins. For instance, how kinetin
is internalized and metabolized by mammalian cells [35], and what are the other drug
target sites in mammalian cells where kinetin binds and invokes both anti-inflammatory
and cytotoxic effects in various concentrations [26]. Therefore, a holistic approach of
assessing time-resolved transcriptomes and metabolomes (including further lipids such
as cholesterol and triglycerides) will be required to dissect the molecular mechanisms
of kinetin biology in mammalian cells. Moreover, large scale, small, molecule-protein
interaction studies [36] will also help shed light on the kinetin regulated pathways as drug
target sites in mammalian cells. The outcome of these analyses will further unleash the
potential of kinetin as a next generation of pharmaceutical agents [37,38] with modulatory
effects against pathophysiological conditions arising from pathogen infection, diabetes, or
cardiovascular complications.
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Figure A1. Metanalysis of the A2a-R gene expression in various tissues of Rattus Norvegicus. GENEVESTIGATOR
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